Kunming Longjin Pharmaceutical Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Kunming Longjin Pharmaceutical Co., Ltd. (002750) was established on September 16, 1996, with a registered capital of RMB 400.5 million. Longjin Runshi, Kangze Cangsheng "- is the original intention of Longjin Pharmaceutical's establishment. Longjin Pharmaceutical's mission is to protect life, improve human health, and share a comfortable life. We have always adhered to the values of craftsmanship, win-win situation, innovation, integrity, and pragmatism. Longjin Pharmaceutical is committed to becoming an industry leader with an innovative spirit, respected by the world, and long-term trust from its partners. Longjin Pharmaceutical focuses on the development, research, production, and sales of therapeutic drugs in the fields of cardiovascular and metabolic diseases. Longjin Pharmaceutical has been awarded multiple national level projects, including the 2018 special project for preclinical research on major new drug creation during the 13th Five Year Plan period, the 2016 special project for traditional Chinese medicine standardization jointly implemented by the National Development and Reform Commission and the Chinese Medical Administration, the 2012 special project for technological transformation of major new drug creation varieties during the 12th Five Year Plan period by the Ministry of Science and Technology, and the 2010 special project for industrial revitalization by the National Development and Reform Commission. The company's leading product is Longjin Injection Breviscapine Lyophilized Powder Injection. Our company has been committed to in-depth research on the formula and preparation process of injection breviscapine products for many years, and has mastered relevant core technologies. The quality standard for injection breviscapine drafted by the company has been included in the Chinese Pharmacopoeia and is the only single ingredient formulation with a purity of 98%. The company has obtained a total of 17 national invention patents for this product from raw materials to formulations. At present, the company has nearly 30 domestic and foreign invention patents. In 2016, the company's intelligent factory construction project was officially launched. Through the three major integrations of "full supply chain integration, full information integration, and full automation integration", Longjin Pharmaceutical was built into a "high-quality, high-efficiency, and low energy consumption" pharmaceutical industry intelligent manufacturing benchmark enterprise. At present, the company's production and operation situation is good, and it is a high-tech pharmaceutical enterprise with rapid growth and development in Yunnan Province. It is one of the top 100 non-public enterprises in Yunnan Province, a leading enterprise in strategic emerging industries in Yunnan Province, and a pilot demonstration enterprise for intelligent manufacturing in Yunnan Province. |
| Headquarter | Kunming |
| Establish Date | 9/16/1996 |
| Listed Code | 002750.SZ |
| Listed Date | 3/24/2015 |
| Chairman | Fan Xianru. |
| CEO | Fan Lijuan. |
| Website | www.longjin.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
